98%
921
2 minutes
20
Motivation: With the booming of interactome studies, a lot of interactions can be measured in a high throughput way and large scale datasets are available. It is becoming apparent that many different types of interactions can be potential drug targets. Compared with inhibition of a single protein, inhibition of protein-protein interaction (PPI) is promising to improve the specificity with fewer adverse side-effects. Also it greatly broadens the drug target search space, which makes the drug target discovery difficult. Computational methods are highly desired to efficiently provide candidates for further experiments and hold the promise to greatly accelerate the discovery of novel drug targets.
Results: Here, we propose a machine learning method to predict PPI targets in a genomic-wide scale. Specifically, we develop a computational method, named as PrePPItar, to Predict PPIs as drug targets by uncovering the potential associations between drugs and PPIs. First, we survey the databases and manually construct a gold-standard positive dataset for drug and PPI interactions. This effort leads to a dataset with 227 associations among 63 PPIs and 113 FDA-approved drugs and allows us to build models to learn the association rules from the data. Second, we characterize drugs by profiling in chemical structure, drug ATC-code annotation, and side-effect space and represent PPI similarity by a symmetrical S-kernel based on protein amino acid sequence. Then the drugs and PPIs are correlated by Kronecker product kernel. Finally, a support vector machine (SVM), is trained to predict novel associations between drugs and PPIs. We validate our PrePPItar method on the well-established gold-standard dataset by cross-validation. We find that all chemical structure, drug ATC-code, and side-effect information are predictive for PPI target. Moreover, we can increase the PPI target prediction coverage by integrating multiple data sources. Follow-up database search and pathway analysis indicate that our new predictions are worthy of future experimental validation.
Conclusion: In conclusion, PrePPItar can serve as a useful tool for PPI target discovery and provides a general heterogeneous data integrative framework.
Availability And Implementation: PrePPItar is available at http://doc.aporc.org/wiki/PrePPItar.
Contact: ycwang@nwipb.cas.cn or ywang@amss.ac.cn
Supplementary Information: Supplementary data are available at Bioinformatics online.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1093/bioinformatics/btv528 | DOI Listing |
Expert Opin Drug Discov
September 2025
Biotechnological Center, CMCB and scads.ai, Dresden, Germany.
Background: Promiscuity of drugs and targets plays an important role in drug-target prediction, ranging from the explanation of side effects to their exploitation in drug repositioning. A specific form of promiscuity concerns drugs, which interfere with protein-protein interactions. With the rising importance of such drugs in drug discovery and with the large-scale availability of structural data, the question arises on the structural basis of this form of promiscuity and the commonalities of the underlying protein-ligand (PLI) and protein-protein interactions (PPI).
View Article and Find Full Text PDFGeorgian Med News
June 2025
2Private Practice, Prishtina, Kosovo.
Objective: This narrative review examines the impact of systemic drugs, including antibiotics and non-antibiotic medications, on the oral and gut microbiomes, highlighting mechanisms of microbial alteration and clinical implications.
Methodology: A comprehensive literature search was performed using PubMed, Scopus, and Web of Science for studies published from 2014 to 2025. Keywords included "systemic drugs," "oral microbiome," "gut microbiome," and "dysbiosis.
Over the past decades, acid production in the stomach has been regulated mainly by proton pump inhibitors (PPIs). However, despite their widespread use and solid evidence base for efficacy, PPIs have pharmacokinetic and pharmacodynamic limitations, such as a slow onset of action, response variability (dependent on CYP2C19 polymorphisms), and the need for activation in an acidic environment. These restrictions underscore the need for innovative molecular approaches to inhibiting acid production, which led to the development of a fundamentally different mechanism of action - potassium-competitive acid blockers (P-CABs), first introduced into clinical practice in 2015.
View Article and Find Full Text PDFSci Rep
August 2025
Department of Pharmacy, Ningbo Yinzhou No.2 Hospital, Ningbo, 315100, Zhejiang, China.
Proton pump inhibitors (PPIs) are a class of drugs that inhibit gastric acid secretion and are commonly overused in clinical practice. We developed a quality control circle (QCC) assisted by artificial intelligence (AI) and led by clinical pharmacists to improve rational PPI use among patients in our hospital. A QCC team was established to follow QCC procedures.
View Article and Find Full Text PDFCancer Res Commun
August 2025
The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Concurrent use of medications can modulate the effectiveness of immunotherapy. Although this interaction is well documented for immune checkpoint inhibitors, whether this occurs with new experimental compounds has not been evaluated. A computerized data extraction tool was used to collect clinical data and identify the prescription of a predefined set of medications within 30 days of immunotherapy infusion in the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center.
View Article and Find Full Text PDF